Patent ID: 9365828
Filing Date: 2016-06-14
CPC Classification: A61K,A61P,C12N

Claim Text:
1. A method of treating Amyotrophic Lateral Sclerosis (ALS), comprising intramuscularly administering to a subject in need thereof a therapeutically effective amount of the isolated cell population which comprises at least four subpopulations of muscle progenitor cells, each of the at least four subpopulations being distinct in that they are genetically modified to express a different neurotrophic factor, wherein the neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF), thereby treating ALS.